Neuro-feedback For Improved Efficacy Of Retinal Prostheses
Funder
National Health and Medical Research Council
Funding Amount
$653,655.00
Summary
Bionic eyes offer the possibility to return sight to the blind. Existing retinal implants are effective at delivering basic visual percepts, namely brief spots of light. Our team is now working on building the second generation of bionic eyes that include the ability to both stimulate the visual system (the retina) and record its response. By recording the evoked responses, we can adjust and optimize the stimulation to restore a persistent high spatial resolution sense of vision to the blind.
Virus Vaccines That Ensure Preparedness Against Future Public Health Emergencies
Funder
National Health and Medical Research Council
Funding Amount
$862,061.00
Summary
In this proposal, we will utilize novel technology we have developed (the molecular clamp) to generate candidate subunit vaccines and therapeutic antibody treatments against four highly pathogenic viruses identified by the World Health Organization as requiring urgent R&D to prepare for future epidemics; Ebola virus, Middle East Respiratory Coronavirus, Nipah virus and Lassa fever virus. Resulting vaccines are expected to provide advantages including safety, efficacy, and thermal stability.
Structural Studies On The Immune Effector Perforin: Developing Mechanism-based Inhibitors
Funder
National Health and Medical Research Council
Funding Amount
$1,116,594.00
Summary
Perforin is an essential weapon deployed by the human immune cells in order to destroy virally infected or cancerous cells. Despite this key role, unwanted or excessive perforin function can result in disease and can severely impact on successful treatment of leukaemia through bone marrow transplantation. This application aims to understand the molecular details of perforin function, and to apply this knowledge to develop perforin inhibitors.
Novel Dual Domain Targeting Strategies Against ErbB Receptors
Funder
National Health and Medical Research Council
Funding Amount
$711,216.00
Summary
This project will develop innovative strategies to treat cancer through novel antibodies to erbB growth factor receptors, and identify ways to improve conventional treatments.
Improving Spatial Resolution In Retinal Prostheses Through Novel Electrical Stimulation Techniques
Funder
National Health and Medical Research Council
Funding Amount
$371,390.00
Summary
This project aims to improve the resolution of bionic eyes and thus improve quality of living for the blind through novel electrical stimulation methods. Present commercial implants are inadequate in the amount of resolution they provide to conduct complex tasks such as independent navigation, reading and facial recognition. The proposed experiments using the new stimulation methods will inform a new generation of devices capable of high resolution without increasing the number of physical elect ....This project aims to improve the resolution of bionic eyes and thus improve quality of living for the blind through novel electrical stimulation methods. Present commercial implants are inadequate in the amount of resolution they provide to conduct complex tasks such as independent navigation, reading and facial recognition. The proposed experiments using the new stimulation methods will inform a new generation of devices capable of high resolution without increasing the number of physical electrodes.Read moreRead less
We aim to develop a new class of cholesterol-lowering drugs by blocking the interaction between a protein in the blood called PCSK9 and its receptor, which is implicated in cholesterol absorption. We will do this by designing small stable peptides (mini proteins) that mimic part of the receptor and have the potential to interfere with the normal PCSK9 binding process. These drugs should be less expensive and potentially less immunogenic than competing therapies based on antibodies.
Resolving And Targeting The Complex Molecular Mechanisms Underlying GPCR Signalling
Funder
National Health and Medical Research Council
Funding Amount
$1,071,370.00
Summary
Receptors are located on the surface of all human cells to allow our cells to respond to their environment. Over 30% of prescription drugs act through particular receptors called GPCRs, however effective drugs without side effects are difficult to develop because we do not have a deep understanding of how GPCRs transmit complex signals. In this proposal we seek to resolve the atomic-level details of GPCR signalling to assist in the development of better drugs for a diverse range of diseases.
Design And Delivery Of Peptide-based Anti-cancer Grb7 Inhibitors
Funder
National Health and Medical Research Council
Funding Amount
$603,126.00
Summary
The Grb7 protein is overproduced in many types of cancer cells and plays a role in cancer cell growth and spread. The current proposal builds upon the discovery of a peptide-based Grb7 inhibitor that has anti-cancer activity. This proposal is to prepare more potent inhibitor molecules that can efficiently reach the target cancer cells. Such molecules will be used for the study of Grb7 and for the development of a new Grb7-based anti-cancer drug therapy.
Development Of Peptide-based Scaffolds For Intracellular Cancer Targets
Funder
National Health and Medical Research Council
Funding Amount
$1,479,836.00
Summary
The overall aim of this project is to develop peptide-based drugs that are able to cross cell membranes and inhibit specific targets inside cells leading to more effective, safer and cost effective drugs for cancer. One potential outcome of the project will be new drug leads to treat melanoma and leukemia that are likely to be less toxic, more potent and less likely to develop resistance than current treatments.
Unraveling Fibrosis By Pharmacological Targeting Of The G Protein-coupled Receptor, RXFP1
Funder
National Health and Medical Research Council
Funding Amount
$798,618.00
Summary
Peptides, with their high specificity and low toxicity profiles, are highly attractive alternatives to small molecule drugs. H2 relaxin, a peptide hormone, has a strong potential for treating fibrosis. However, the large size of H2 relaxin makes it difficult and expensive to manufacture. Once administered to patients, it is also quickly degraded. We have developed a small anti-fibrotic relaxin peptide, and propose to understand its mechanism of action and improve its therapeutic indices.